GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Itonis Inc (OTCPK:ITNS) » Definitions » Return-on-Tangible-Equity

Itonis (Itonis) Return-on-Tangible-Equity : 0.00% (As of Feb. 2008)


View and export this data going back to 2007. Start your Free Trial

What is Itonis Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Itonis's annualized net income for the quarter that ended in Feb. 2008 was $-1.67 Mil. Itonis's average shareholder tangible equity for the quarter that ended in Feb. 2008 was $-0.98 Mil. Therefore, Itonis's annualized Return-on-Tangible-Equity for the quarter that ended in Feb. 2008 was N/A%.

The historical rank and industry rank for Itonis's Return-on-Tangible-Equity or its related term are showing as below:

ITNS's Return-on-Tangible-Equity is not ranked *
in the Medical Distribution industry.
Industry Median: 8.37
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Itonis Return-on-Tangible-Equity Historical Data

The historical data trend for Itonis's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Itonis Return-on-Tangible-Equity Chart

Itonis Annual Data
Trend Nov05 Nov06 Nov07
Return-on-Tangible-Equity
-1,008.11 - -

Itonis Quarterly Data
Nov05 Feb06 May06 Aug06 Nov06 Feb07 May07 Aug07 Nov07 Feb08
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Itonis's Return-on-Tangible-Equity

For the Medical Distribution subindustry, Itonis's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Itonis's Return-on-Tangible-Equity Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Itonis's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Itonis's Return-on-Tangible-Equity falls into.



Itonis Return-on-Tangible-Equity Calculation

Itonis's annualized Return-on-Tangible-Equity for the fiscal year that ended in Nov. 2007 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Nov. 2007 )  (A: Nov. 2006 )(A: Nov. 2007 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Nov. 2007 )  (A: Nov. 2006 )(A: Nov. 2007 )
=-1.398/( (-0.395+-1.081 )/ 2 )
=-1.398/-0.738
=N/A %

Itonis's annualized Return-on-Tangible-Equity for the quarter that ended in Feb. 2008 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Feb. 2008 )  (Q: Nov. 2007 )(Q: Feb. 2008 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Feb. 2008 )  (Q: Nov. 2007 )(Q: Feb. 2008 )
=-1.668/( (-1.081+-0.874)/ 2 )
=-1.668/-0.9775
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Feb. 2008) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Itonis  (OTCPK:ITNS) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Itonis Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Itonis's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Itonis (Itonis) Business Description

Traded in Other Exchanges
N/A
Address
22600-C Lambert Street, Suite 902, Lake Forest, CA, USA, 92630
Itonis Inc is a development-stage company. It operates as a holding company, which engages in the development and distribution of products to the medical and pharmaceutical industry. It is presently focused on marketing its Emesyl homeopathic anti-nausea product for retail sale. It produces and markets over-the-counter and prescription homeopathic preparations to treat both common ailments and chronic diseases.

Itonis (Itonis) Headlines